Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225156 · ClinicalTrials.gov registry record · Phase 3
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
A Phase 3 study, sponsored by argenx.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT04225156 is a Phase 3 study that has completed, run by argenx. The registered enrollment target is 101 participants.
The verdict
NCT04225156, a Phase 3 study, has completed, sponsored by argenx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
Interventions
- BIOLOGICAL efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2026-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225156
The ClinicalTrials.gov registry entry for NCT04225156 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efgartigimod is the first listed.
NCT04225156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04225156 about?
NCT04225156 is a clinical study titled "A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).". This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
What is the current status of trial NCT04225156?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2020-06-02. Estimated completion is 2026-03-11.
What interventions are being tested in trial NCT04225156?
The interventions under investigation include: efgartigimod (BIOLOGICAL).
Who is sponsoring clinical trial NCT04225156?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.